首页 | 本学科首页   官方微博 | 高级检索  
     

雄激素剥夺疗法和免疫疗法在前列腺癌治疗中的研究进展
引用本文:朱晖,邓康俐. 雄激素剥夺疗法和免疫疗法在前列腺癌治疗中的研究进展[J]. 肿瘤防治研究, 2019, 46(10): 867-872. DOI: 10.3971/j.issn.1000-8578.2019.19.0787
作者姓名:朱晖  邓康俐
作者单位:1. 44195 克利夫兰,美国克利夫兰医学中心格里克曼泌尿及肾脏研究所;2. 430079 武汉,湖北省肿瘤医院泌尿外科
摘    要:前列腺癌在美国成年男性中发病率位居第一,癌症相关致死率位居第二。雄激素剥夺治疗是最常用的前列腺癌治疗方法,而且通常伴随患者的终身治疗。雄激素和雄激素剥夺疗法对免疫系统有着重要的影响,在目前免疫治疗受到持续关注的情况下这一发现显得尤为重要。研究表明,雄激素剥夺治疗可能对免疫治疗起到促进或者抑制的作用。本文综述了不同类型雄激素剥夺治疗药物的作用机制,探讨了其对前列腺癌细胞及患者免疫系统的影响,以及联合使用雄激素剥夺药物和免疫治疗的前景,为前列腺癌的治疗提供了新的视野和思路。

关 键 词:雄激素剥夺治疗  免疫治疗  前列腺癌  
收稿时间:2019-06-14

A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer
ZHU Hui,DENG Kangli. A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer[J]. Cancer Research on Prevention and Treatment, 2019, 46(10): 867-872. DOI: 10.3971/j.issn.1000-8578.2019.19.0787
Authors:ZHU Hui  DENG Kangli
Affiliation:1. Glickman Urologic and Kidney Institute, Cleveland Clinic, 9500 Euclid Ave. Q100, Cleveland, OH 44195, USA; 2. Department of Urology, Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan 430079, China
Abstract:Prostate cancer ranks first among adult males in the United States, and second in cancer-related mortality. Androgen deprivation therapy (ADT) is the most commonly used treatment for prostate cancer and is usually a lifelong treatment with the patient. Androgen and ADT have a profound impact on the immune system, and this finding is particularly important in the ear of current immunotherapy. Studies have shown that ADT may promote or inhibit immunotherapy. This article reviews the mechanism of action of different types of ADT drugs, discusses their effects on prostate cancer cells and immune system, and the prospect of combination of ADT and immunotherapy, to provide new thought and vision on the treatment of prostate cancer.
Keywords:Androgen deprivation therapy  Immunotherapy  Prostate cancer  
点击此处可从《肿瘤防治研究》浏览原始摘要信息
点击此处可从《肿瘤防治研究》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号